依普利酮图片及介绍

Introduction of India's Lupine Pharmaceuticals: India's Lupine Pharmaceuticals eplerenone (Planep) is a new type of selective aldosterone receptor antagonist with extremely low affinity for androgen and progesterone receptors and few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. It is a good alternative to spironolactone. For severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction.

Pictures of eplerenone from Lupine Pharmaceuticals in India:

Eplerenone from India's Lupine Pharmaceuticals can selectively act on aldosterone receptors and is highly selective for mineralocorticoid receptors, but has less effect on androgen and progesterone receptors. Its affinity for mineralocorticoids is 15 to 20 times that of spironolactone. Eplerenone treats patients with stage 1 and stage 2 hypertension with similar efficacy rates and reductions in systolic and diastolic blood pressure as enalapril. Eplerenone also has a good antihypertensive effect in patients with essential hypertension with low renin levels for whom angiotensin-converting enzyme inhibitors and angiotensin II receptor inhibitors are not effective. It also has a good antihypertensive effect on simple systolic hypertension, and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, (Planep) can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for patients with hypertension combined with diabetes.

Recommended related hot articles: /newsDetail/86624.html